BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 20, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2001

View Archived Issues

Inflazyme and Helicon to study drug leads related to learning and memory

Read More

Bristol-Myers Squibb to conduct Glucovance trial in pediatric type 2 diabetes

Read More

Telik and Sanwa Kagaku extend drug discovery alliance for second time

Read More

Genome Therapeutics to identify DNA map of pathogenic organism for Wyeth Lederle Vaccines

Read More

Aviron highlights Q4 and year-end 2000 developments

Read More

Repligen updates product development programs

Read More

University of Iowa licenses AAV technology to Targeted Genetics

Read More

Schering-Plough identifies novel antifungal agents that damage the fungal cell wall

Read More

Curvularol: a naturally produced cell cycle inhibitor

Read More

In vitro study provides support for development of CS-891 as Rx for alopecia

Read More

Novel vaccine approach warrants further evaluation in pancreatic cancer

Read More

Genta licenses antisense technology to Atugen

Read More

Abgenix and Celltech enter license and codevelopment agreement based on SLAM technology

Read More

Candidate AGE formation inhibitor exhibits renoprotective effects in diabetic rats

Read More

Lundbeck buys out Byk Gulden in German joint venture

Read More

Demegen to expand cancer research

Read More

SCIO-469 now being studied in phase Ib trial for treatment of RA

Read More

Clinical data on BMS-232632 presented at Chicago conference

Read More

Durect setting fast pace in phase II DUROS sufentanil trial for chronic pain

Read More

Avax subsidiary to evaluate TK suicide gene therapy technology

Read More

Phase III trial of irofulven in pancreatic cancer proceeds on schedule

Read More

BCH-10618 shows favorable resistance profile in cell culture experiments

Read More

Preclinical studies point to role for ACH-126443 in combination anti-HIV therapy

Read More

Ivax acquires Lilly's talampanel, an advanced-stage antiepileptic

Read More

Selective Y1 receptor antagonists and their use described by BMS

Read More

Antiviral agents designed at Biota are reportedly superior to pirodavir

Read More

Recent patent covers new antibacterial quinoline derivatives

Read More

Former SmithKline Beecham provides macrophage scavenger receptor antagonists

Read More

ISIS-28030: a new antisense inhibitor of PI3K p85

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing